阿帕替尼联合卡培他滨三线治疗晚期三阴性乳腺癌的效果

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (30 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate effect of third-line therapy of Apatinib combined with Capecitabine on the advanced triple negative breast cancer (TNBC). Methods A total of 78 patients with advanced TNBC who failed secondline chemotherapy in Anshan Cancer Hospital from May 2018 to May 2019 were selected and randomly divided into study group and reference group, with 39 cases in each group. The reference group was treated with Capecitabine monotherapy for three-line treatment, and the study group was treated with Apatinib combined with Capecitabine for three-line treatment. The clinical efficacy of the two groups of TNBC patients after treatment was compared, including the objective response rate (ORR)and disease control rate (DCR),the survival rate of the two groups of patients within 1 year after treatment was followed up, and the occurrence of adverse reactions was analyzed. Results The ORR and DCR of the study group were higher than those of the reference group, and the differences were statistically significant (P＜0.05). The survival rate of the study group within 1 year after treatment was higher than that of the reference group, and the difference was statistically significant (P＜0.05). The incidence of hypertension in the study group was higher than that in the reference group, and the difference was statistically significant (P＜0.05); there was no significant difference in other adverse reactions between the two groups (P＞0.05). Conclusion During the third line treatment of advanced TNBC patients, the short-term curative effect of Apatinib combined with Capecitabine chemotherapy regimen is considerable, which can improve the survival rate of the patients to a certain extent, and the adverse reactions are in a tolerant state.

Key words： Apatinib Capecitabine Third-line chemotherapy Advanced triple-negative breast cancer Clinical efficacy

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	XU Ning
	WANG Yan-ru

Cite this article:

XU Ning,WANG Yan-ru. Effect of third-line therapy of Apatinib combined with Capecitabine on advanced triple negative breast cancer[J]. 中国当代医药, 2021, 28(28): 145-147-156.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2021/V28/I28/145

[1]	陈怡安，贾红燕，张萌萌，等.35 岁以下三阴性乳腺癌临床病理特征及预后分析[J].海南医学，2019，30（13）：1657-1663.
[2]	廖瑜倩，樊英，万以叶，等.长春瑞滨联合卡培他滨治疗晚期三阴性乳腺癌的疗效及生存观察[J].中国肿瘤临床与康复，2012，19（2）：150-152.
[3]	刘君，肖扬，郭建雄，等.奥沙利铂联合替吉奥和吉西他滨联合顺铂治疗晚期三阴性乳腺癌的疗效和不良反应比较[J].肿瘤防治研究，2016，25（1）：72-77.
[4]	李义慧，周洋，刘媛媛，等.应用PEM-D 系统评估阿帕替尼治疗晚期乳腺癌患者后整体心身变化及疗效观察[J].中国医药，2020，15（6）：100-103.
[5]	单宏杰，肖迎利，李红，等.低剂量阿帕替尼联合卡培他滨在多线治疗失败的晚期乳腺癌中的疗效观察[J].重庆医学，2019，48（16）：2800-2803.
[6]	王红梅，赵阳，刘文楼，等.低剂量阿帕替尼联合口服化疗药治疗晚期难治性乳腺癌的临床观察[J].徐州医科大学学报，2018，25（12）：781-786.
[7]	孟洪汭，王潍博.阿帕替尼联合卡培他滨三线治疗晚期三阴性乳腺癌的疗效观察[J].中国医院用药评价与分析，2019，19（6）：670-672，676.
[8]	Cancer N.Common Terminology Criteria for Adverse Events（CTCAE）v4.0[J].https://ctep.cancer.gov.2009.
[9]	张伟杰，沈雪敬，李冬荟，等.阿帕替尼单药治疗晚期三阴性乳腺癌的临床疗效及安全性[J].肿瘤基础与临床，2019，30（4）：283-287
[10]	冯飞，侯娟，吴志伟，等.阿帕替尼及卡培他滨治疗晚期胃癌的疗效及不良反应观察[J].医药界，2019，20（23）：1.
[11]	包久铭，高艳梅，邱华凉，等.甲磺酸阿帕替尼片联合卡培他滨片和奥沙利铂注射剂治疗晚期结直肠癌的临床研究[J].中国临床药理学杂志，2019，22（15）：1565-1567.
[12]	韩娜娜，闫兵杰，陈怡哲.低剂量阿帕替尼联合XD 化疗方案治疗晚期乳腺癌患者临床研究[J].现代医药卫生，2019，35（3）：422-424.
[13]	黄芳.阿帕替尼联合GP 方案二线及以上治疗晚期复发三阴性乳腺癌的疗效分析[J].中国实用医药，2020，15（4）：24-26.
[14]	田美娟，王丽，张佳，等.口服小剂量环磷酰胺联合卡培他滨维持治疗晚期三阴性乳腺癌的疗效[J].现代肿瘤医学，2019，27（12）：70-73.
[15]	王爱娟，过怿赟，汪志求.阿帕替尼联合卡培他滨三线治疗晚期三阴性乳腺癌的临床观察[J].中国临床药理学与治疗学，2020，25（4）：78-84.